title: Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
abstract: BACKGROUND
  Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.
  
  
  METHODS
  Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
  
  
  RESULTS
  A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).
  
  
  CONCLUSIONS
  Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.
authors.affiliation: Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Klinikstr 6-8, 97070 Würzburg, Germany.
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Tony
authors.forename: Gerd
authors.initials: G
authors.lastname: Burmester
authors.forename: Hendrik
authors.initials: H
authors.lastname: Schulze-Koops
authors.forename: Mathias
authors.initials: M
authors.lastname: Grunke
authors.forename: Joerg
authors.initials: J
authors.lastname: Henes
authors.forename: Ina
authors.initials: I
authors.lastname: Kötter
authors.forename: Judith
authors.initials: J
authors.lastname: Haas
authors.forename: Leonore
authors.initials: L
authors.lastname: Unger
authors.forename: Svjetlana
authors.initials: S
authors.lastname: Lovric
authors.forename: Marion
authors.initials: M
authors.lastname: Haubitz
authors.forename: Rebecca
authors.initials: R
authors.lastname: Fischer-Betz
authors.forename: Gamal
authors.initials: G
authors.lastname: Chehab
authors.forename: Andrea
authors.initials: A
authors.lastname: Rubbert-Roth
authors.forename: Christof
authors.initials: C
authors.lastname: Specker
authors.forename: Jutta
authors.initials: J
authors.lastname: Weinerth
authors.forename: Julia
authors.initials: J
authors.lastname: Holle
authors.forename: Ulf
authors.initials: U
authors.lastname: Müller-Ladner
authors.forename: Ramona
authors.initials: R
authors.lastname: König
authors.forename: Christoph
authors.initials: C
authors.lastname: Fiehn
authors.forename: Philip
authors.initials: P
authors.lastname: Burgwinkel
authors.forename: Klemens
authors.initials: K
authors.lastname: Budde
authors.forename: Helmut
authors.initials: H
authors.lastname: Sörensen
authors.forename: Michael
authors.initials: M
authors.lastname: Meurer
authors.forename: Martin
authors.initials: M
authors.lastname: Aringer
authors.forename: Bernd
authors.initials: B
authors.lastname: Kieseier
authors.forename: Cornelia
authors.initials: C
authors.lastname: Erfurt-Berge
authors.forename: Michael
authors.initials: M
authors.lastname: Sticherling
authors.forename: Roland
authors.initials: R
authors.lastname: Veelken
authors.forename: Ulf
authors.initials: U
authors.lastname: Ziemann
authors.forename: Frank
authors.initials: F
authors.lastname: Strutz
authors.forename: Praxis
authors.initials: P
authors.lastname: von Wussow
authors.forename: Florian M P
authors.initials: FM
authors.lastname: Meier
authors.forename: Nico
authors.initials: N
authors.lastname: Hunzelmann
authors.forename: Enno
authors.initials: E
authors.lastname: Schmidt
authors.forename: Raoul
authors.initials: R
authors.lastname: Bergner
authors.forename: Andreas
authors.initials: A
authors.lastname: Schwarting
authors.forename: Rüdiger
authors.initials: R
authors.lastname: Eming
authors.forename: Michael
authors.initials: M
authors.lastname: Hertl
authors.forename: Rudolf
authors.initials: R
authors.lastname: Stadler
authors.forename: Michael
authors.initials: M
authors.lastname: Schwarz-Eywill
authors.forename: Siegfried
authors.initials: S
authors.lastname: Wassenberg
authors.forename: Martin
authors.initials: M
authors.lastname: Fleck
authors.forename: Claudia
authors.initials: C
authors.lastname: Metzler
authors.forename: Uwe
authors.initials: U
authors.lastname: Zettl
authors.forename: Jens
authors.initials: J
authors.lastname: Westphal
authors.forename: Stefan
authors.initials: S
authors.lastname: Heitmann
authors.forename: Anna L
authors.initials: AL
authors.lastname: Herzog
authors.forename: Heinz
authors.initials: H
authors.lastname: Wiendl
authors.forename: Waltraud
authors.initials: W
authors.lastname: Jakob
authors.forename: Elvira
authors.initials: E
authors.lastname: Schmidt
authors.forename: Klaus
authors.initials: K
authors.lastname: Freivogel
authors.forename: Thomas
authors.initials: T
authors.lastname: Dörner
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000401:mortality; D004342:Drug Hypersensitivity / Q000453:epidemiology; D004351:Drug Resistance / Q000276:immunology; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006304:Health Status; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D017060:Patient Satisfaction; D012042:Registries / Q000706:statistics & numerical data; D012189:Retrospective Studies; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab